News For NVS;MOS;SCCO;ADM;IP From The Last 14 Days
Check below for free stories on NVS;MOS;SCCO;ADM;IP the last two weeks.
|July 17, 2014|
|05:32 EDT||NVS||Novartis reconfirms FY14 revenue guidance up at low to mid single digit rate|
The company stated, "We are reconfirming our outlook for FY14. Group net sales in 2014 are expected to grow at a low to mid-single digit rate. Group core operating income is expected to grow ahead of sales in 2014, and now refined to mid to high-single digit. This outlook recognizes the entry of generic competition for Diovan monotherapy in the U.S. on July 7, including an authorized generic from Sandoz on the same date. If June average exchange rates prevail for the remainder of the year, the currency impact for the year would be -1% on sales and -3% to -4% on core operating income."
|05:29 EDT||NVS||Novartis reports Q2 Core EPS $1.34, consensus $1.42|
Reports Q2 revenue $14.6B, consensus $14.81B. Reports continued pipeline progress with positive regulatory decisions and significant clinical trial data released in Q2.
|July 15, 2014|
|05:44 EDT||NVS||Novartis to license Google 'smart lens' technology|
Novartis (NVS) announced that its eye care division Alcon has entered into an agreement with a division of Google (GOOG) to in-license its "smart lens" technology for all ocular medical uses. The agreement with Google[x], a team within Google that is devoted to finding new solutions to big global problems, provides Alcon with the opportunity to develop and commercialize Google's "smart lens" technology with the potential to transform eye care and further enhance Alcon's pipeline and global leadership in contact lenses and intraocular lenses. The transaction remains subject to anti-trust approvals. The agreement between Google and Alcon represents an important step for Novartis, across all of its divisions, to leverage technology to manage human diseases and conditions. Google's key advances in the miniaturization of electronics complement Novartis's deep pharmaceuticals and medical device expertise. Novartis aims to enhance the ways in which diseases are mapped within the body and ultimately prevented.
|05:35 EDT||NVS||Novartis collaborates with Banner Alzheimer's Institute on study|
Novartis announced a collaboration with Banner Alzheimer's Institute, or BAI, on a pioneering clinical study in Alzheimer's disease, or AD, prevention. The study will determine whether two Novartis investigational anti-amyloid treatments can prevent or delay the emergence of symptoms of AD in people identified as being at genetic risk for developing the late-onset form of the disease. Using an innovative trial design, the two treatments will be given in cognitively healthy people at genetic risk of developing the build-up of amyloid protein in the brain that may eventually lead to AD. One treatment is an active immunotherapy, a treatment that stimulates an immune response, and triggers the production of natural antibodies against amyloid. This investigational treatment, given via an injection, is in phase II clinical development. The second treatment, a BACE inhibitor, is an oral medication about to enter phase I trials and is designed to prevent the production of different forms of amyloid.
|July 14, 2014|
|10:00 EDT||IP||On The Fly: Analyst Downgrade Summary|
Subscribe for More Information
|07:56 EDT||IP||International Paper downgraded to Neutral from Buy at Buckingham|
Buckingham downgraded International Paper to Neutral to reflect the recent softness in white paper and sluggish container-board demand. Price target is $52.
|07:23 EDT||NVS||Alzheimer's Association to hold a conference|
Subscribe for More Information